Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Coherus BioSciences Price Performance
NASDAQ:CHRS traded up $1.11 on Friday, reaching $13.76. The company's stock had a trading volume of 1,238,439 shares, compared to its average volume of 1,210,397. Coherus BioSciences has a twelve month low of $5.60 and a twelve month high of $19.32. The company has a debt-to-equity ratio of 33.47, a current ratio of 3.17 and a quick ratio of 2.95. The firm's 50 day moving average is $8.31 and its two-hundred day moving average is $9.97.
Coherus BioSciences (NASDAQ:CHRS - Get Rating) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.17. Coherus BioSciences had a negative net margin of 83.47% and a negative return on equity of 422.10%. During the same period in the prior year, the company posted ($0.40) EPS. As a group, equities research analysts forecast that Coherus BioSciences will post -3.42 EPS for the current fiscal year.
Analysts Set New Price Targets
CHRS has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Coherus BioSciences in a research note on Tuesday, May 3rd. Mizuho decreased their target price on shares of Coherus BioSciences from $30.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, May 20th. Barclays dropped their price target on shares of Coherus BioSciences from $20.00 to $15.00 in a research report on Monday, May 9th. Finally, UBS Group initiated coverage on shares of Coherus BioSciences in a report on Monday, June 13th. They issued a "neutral" rating and a $7.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Coherus BioSciences presently has an average rating of "Hold" and a consensus price target of $18.40.